Navigation Links
John Theurer Cancer Center Announces Positive Results from Revlimid MCL-001(EMERGE) Study Leading to FDA Approval of First Oral Therapy for Refractory Mantle-Cell Lymphoma (MCL) Patients
Date:9/26/2013

HACKENSACK, N.J., Sept. 26, 2013 /PRNewswire/ -- Andre Goy, M.D., M.S., Chairman and Director of John Theurer Cancer Center and Chief of the Lymphoma Program, has just published two important papers in relapsed/refractory mantle-cell lymphoma (MCL) in the Journal of Clinical Oncology and New England Journal of Medicine. MCL is a difficult subtype of non-Hodgkin lymphoma, where patients often become chemoresistant after responding to initial therapy.

Dr. Goy, an international expert in the field, led the lenalidomide global pivotal trial known as MCL-001 or EMERGE trial. Lenalidomide belongs to a category of immunomodulators that is first-in-class approved for lymphoma. This Phase II study showed that lenalidomide induced rapid and prolonged response in patients who were heavily pretreated regardless of the number of their prior regimens and with a median duration of response of more than 16 months. Many of these patients had also been refractory to their last prior therapy. The EMERGE trial results were published in the leading Journal of Clinical Oncology ("Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study" JCO September 2013).

"This trial led to the recent approval by the FDA of lenalidomide as the first oral compound available for that disease addressing a definite unmet need for these patients," said Andre Goy, M.D., M.S., Chairman and Director, and Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates. "Lenalidomide is only the second drug ever approved for the treatment of mantle-cell lymphoma."

The second study was published in the New England Journal of Medicine a few weeks ago in collaboration
'/>"/>

SOURCE John Theurer Cancer Center
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Revolutionary Natural Sunscreen That Can Reverse Wrinkles, Fine Lines, Sagging Skin, Laugh Lines And Potentially Reverse Cancer Cell Formation With Anti-Aging And Anti-Cancer Forming Natural Ingredients Now Available From Rejuve MD
2. New Survey Reveals U.S. Men with Advanced Prostate Cancer Worry More about Burdening Family and Friends Than Dying
3. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
4. Laser-Proton Therapy Working Group Takes Second Look at Ways to Lower Cost of Advanced Cancer Treatment
5. APPLIED INTEGRIN SCIENCES, INC. LAUNCHES CROWDFUNDING CAMPAIGN TO RAISE FUNDS FOR ITS CANCER DRUG DEVELOPMENT PROGRAM
6. In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market
7. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
8. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
9. K94 Discoveries, Inc. Announces Seed Financing To Advance Targeted Drug Conjugates To Treat Pancreatic And Other Cancers
10. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
11. Study Suggests that a Single Session of Stereotactic Body Radiation Therapy (Lung Radiosurgery) is a Promising Approach for Treating Inoperable Early-Stage Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... has announced the addition of the "Investigation ... report to their offering. Developed by ... of Novolog) is an important drug for the ... aspart, as a fast- acting insulin analog, starts ...
(Date:8/28/2015)... 28, 2015 Perrigo Company plc ("Perrigo") (NYSE: ... N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote regarding ... "Our views of Mylan,s offer to Perrigo shareholders have ... our Board,s careful reflection of the value available to ... choices that Mylan has allowed its shareholders to consider," ...
(Date:8/28/2015)... India , August 28, 2015 ... Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by Region ... , Asia-Pacific , and Rest of the ... MarketsandMarkets, The global market for Eubiotics was valued at USD ... 7.05 Billion by 2020, at a CAGR of 7.4% from ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... Columbia Laboratories, Inc. (Nasdaq: CBRX ), ... today confirmed that the Advisory Committee for Reproductive Health ... is scheduled to review Columbia,s New Drug Application (NDA) ... of preterm birth in women with short uterine cervical ...
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... been named to the role of Executive Vice President ... employment with Valeant, which is expected to be December ... Sachs where he was the chief operating officer for ...
Cached Medicine Technology:Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 2Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 3Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 4Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer 2Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer 3
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , The ... PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., ...
(Date:8/29/2015)... ... ... like Toppik , Eau Thermale Avene and Bliss are now available on ... required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations manager. ... the item’s selling price.” , With competitive pricing in the e-commerce market for beauty ...
(Date:8/29/2015)... ... ... popular television program VOICES IN AMERICA, hosted by legendary star of the stage and ... segment to the subject of diabetes. Diabetes is a debilitating health condition that is ... advancements in medical science may prove to be a significant breakthrough that sufferers have ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists are ... children helping children, a thank you to the many creative and generous ways ... the United Methodist initiative to end malaria deaths. , The Columbus Zoo and ...
(Date:8/28/2015)... VA (PRWEB) , ... August ... ... Risk Management for Medical Devices:, Understanding the FDA’s Position and Best Practices ... MD, http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally renowned expert ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5
... A free white paper is now,available to help ... requirements and unannounced surveys at:, http://www.eheinc.com/jcaho.htm . ... 2006,Unannounced Survey Policy within the Environment of Care, ... engineering and consulting firm,the white paper reviews the ...
... AMERIGROUP,Corporation (NYSE: AGP ) today announced that ... Conference on November 27 in New,York City. A ... 27 at 2:00 p.m. Eastern Time, can be accessed ... page. A replay will be,available for 30 days, and ...
... Tool is believed to be first in nation offered by a health ... ... 13 Group Health Incorporated (GHI) has,announced that GHI will provide what ... the nation offered by a health,insurance plan. Effective November 9, 2007, all ...
... Together Cancer Funding Organizations, Advocates, Government Agencies, and Scientists ... ... NEW YORK, Nov. 13 Leadership and senior staff ... met,on November 1-2 along with experts from government agencies, ...
... the University of Southern California,s Mara Mather as the ... This distinguished honor recognizes insightful and innovative publications on ... social sciences. , The award presentation will take place ... held from November 16th - 20th, 2007 in San ...
... have a Made In Israel stamp on it? American donors ... a very good chance it could. , In September 2007, ... Universitys Prof. Yossi Shiloh from the Department of Human Molecular ... tens of thousands more to eight other researchers at the ...
Cached Medicine News:Health News:Free White Paper Details Hospital Strategies for Meeting Joint Commission Compliance Requirements in the Environment of Care 2Health News:GHI Introduces Online Pediatric Health Risk Assessment 2Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 2Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 3Health News:First-Ever Collaborative Summit on Breast Cancer Research Targets New Partnerships and Collaborative Solutions 4Health News:American donors put faith (and dollars) in TAU cancer research 2Health News:American donors put faith (and dollars) in TAU cancer research 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: